VolitionRx, Alcyomics Win $1M for Inflammatory Response Marker Project | GenomeWeb

NEW YORK (GenomeWeb News) – The Belgian diagnostics developer VolitionRx and the UK-based preclinical drug safety testing firm Alcyomics will use a €779,493 ($1 million) grant to develop biomarkers for indicating inflammatory response, the companies said today.

Under the initiative, the partners will seek to identify novel epigenetic biomarkers for early inflammation and rejection responses linked to graft-versus host disease, which can cause complications in hematopoietic stem cell transplantation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.